Spectroscopy Voxel-wise

Slides:



Advertisements
Similar presentations
Assistant Lecturer Of Neurosurgery, Alexandria, Egypt Alex Neuro 2014.
Advertisements

1 Research Update/Review LAE 5/23/08. 2 RIN/Recurrent Disease: The Problem T1 weighted contrast enhanced MRI taken 16 months after completion of radiotherapy.
Inferior Brain Lesions Monitored Using Diffusion Weighted Magnetic Resonance Imaging Lars Ewell 1, Naren Vijayakumar 2, Jeffrey J. Rodriguez 2 and Baldassarre.
Methods to Differentiate Radiation Induced Necrosis and Recurrent Disease in Gliomas Lars Ewell University of Arizona Medical Center Department of Radiation.
Voxel Location Dependence of Brain Metabolites as Determined by Magnetic Resonance Spectroscopy L.Ewell, A. Bhullar and B. Stea—Department of Radiation.
1 MRI Biomarkers for Cancer Assessment October 14, 2011 Jens Jensen Center for Biomedical Imaging and Department of Radiology.
McDaniels – Feb 29, Outline Patient 6 question Patient 11 ADC results Abstract for AAPM conference.
Multimodal Visualization for neurosurgical planning CMPS 261 June 8 th 2010 Uliana Popov.
Metabolic Concentrations and Ratios of Brain Tissue Amarjeet Bhullar, Lars Ewell, Tim McDaniel and Baldassarre Stea Department of Radiation Oncology, The.
Imaging of bevacizumab treated brain: traditional and emerging concepts Asim K. Bag Joel K Cure Aparna Singhal David Wever Asim K. Bag Joel K Cure Aparna.
What can you see by MRI ? Stephen Paisey.
THE CORRELATIONS OF 3D PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING AND DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION MRI IN BRAIN TUMORS Delgerdalai Khashbat,
Differentiation of Peri-Ictal Pseudoprogression from Tumor Recurrence in a Patient with Treated Glioma: Value of Diffusion Weighted and Perfusion Imaging.
QUANTITATIVE MRI OF GLIOBLASTOMA RESPONSE Bruce Rosen, MD, PhD Athinoula A. Martinos Center for Biomedical Imaging, MGH. Future Plans/Upcoming Trials Reproducibility.
Department of Radiology and Imaging Sciences Division of Neuroradiology University School of Medicine.
In vivo MR Spectroscopy
Prediction of Glioblastoma Multiforme Patient Time to Recurrence Using MR Image Features and Gene Expression Nicolasjilwan, M.1·Clifford, R.2·Flanders,
Correlation and fusion of perfusion and spectroscopic MR imaging for the characterisation of brain tumors A. Förschler 1), K. Vester 1), G. Peters 2),
References: [1]S.M. Smith et al. (2004) Advances in functional and structural MR image analysis and implementation in FSL. Neuroimage 23: [2]S.M.
Brain Metabolites in Patients with Asymptomatic Versus Symptomatic HIV-associated neurocognitive disorder: A 7 Tesla MR Spectroscopy Study Mohamed MA,
IsotropicAnisotropic ROLE OF DIFFUSION TENSOR IMAGING (DTI) IN INTRACRANIAL MASSES Abstract Number: 117.
S. Gaudino, V. Lorusso, M. Caulo *, A. Tartaro *, T. Tartaglione, G.M. Di Lella, C. Colosimo Dept. of Bio-imaging and Radiological Sciences, Policlinico.
University of Michigan Department of Radiology Role of MR Spectroscopy in Differentiating Radiation Necrosis from Tumor Recurrence. Effects of radiation.
Comparison among Three Different Reprocessing Technologies for Quantitation and Influence of STEAM and PRESS Sequences on Metabolic Concentration Xiu-Qing.
Magnetic Resonance Spectroscopy of the hippocampus Marton A 1, Bús L 2, Juhos V 3, Rudas G 2, Barsi P 2 1 University of Pécs, 2 SU MR Research Centre 3.
Spectroscopy of the Brain in Primary Lateral Sclerosis J. Taylor 4, D. Powell 2,3, H. Chebrolu, 1,3 A. Andersen 2,3, E. Kasarskis 1, C.D. Smith 1,2,3 1.
Intratumoral topography of CNS gliomas revealed by diffusion tensor imaging: correlations with tumor volume and grade A. Jakab 1, P. Molnár 2, M. Emri.
ASNR 54rd Annual Meeting ASNR 54rd Annual Meeting
Differentiation between Primary Central Nervous System Lymphoma and Glioblastoma on 3T-MR Imaging: Multivariate Analysis M. Kitajima 1, T. Hirai 1, Y.
Neuroimaging of Toxic Encephalopathy
Comparison of cortical perfusion between relapse-remitting multiple sclerosis patients and healthy controls measured using Arterial Spin Labelling MRI.
Abstract Control Number
C3NL Imperial TBI Magnetic resonance spectroscopy in chronic traumatic brain injury: a useful tool? Karl Zimmerman, Gregory Scott, Ines Violante, Claire.
Neurology Resident and Fellow Section
Opportunities for Addressing Unmet Clinical Need in Brain Cancer
1H MRS Characteristics of Cerebral alveolar echinococcosis
M.D. Patel, J. Zhang, G. Mazibrada, N. Davies, V. Sawlani
Teaching NeuroImages Neurology Resident and Fellow Section
Informed consent obtained
MR images analysis of glioma
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
MR Perfusion and Diffusion Values in Gliomas
Hai-Yu Wang, Ye-Yu Xiao, Ren-Hua Wu Department of Medical Imaging
Copyright © 2009 American Medical Association. All rights reserved.
Neuroradiology Department Bellaria Hospital Bologna
Influence of the Non-Linear Fitting Approach on
Fig year-old female patient with two months of headaches and falls and a remote history of right lung lobectomy for reported benign tumor with MR.
IDH1 mutant glioma cells are sensitive to TMZ
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) and Review of Literature Zebin Xiao Department of.
Volume 54, Issue 3, Pages (September 2008)
Computational Neuroanatomy for Dummies
Nat. Rev. Neurol. doi: /nrneurol
Stephen L. Hauser, Jorge R. Oksenberg  Neuron 
Volume 138, Issue 4, Pages (April 2010)
Volume 148, Issue 1, Pages (January 2012)
Volume 29, Issue 5, Pages (May 2016)
Genomic Approaches to High Grade Gliomas
Published online September 20, 2017 by JAMA Surgery
New assessment of hepatic encephalopathy
Introduction to Magnetic Resonance Spectroscopy
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Functional Neuroimaging: a window on the working human brain
Fig. 4 DMI visualizes the Warburg effect in a patient with GBM after oral [6,6′-2H2]glucose intake. DMI visualizes the Warburg effect in a patient with.
A 11-month-old girl with acute irritability and hypotonia
Results Motivation Introduction Methods Conclusions Acknowledgements
Figure 2c.  Left parietal glioblastoma multiforme (WHO grade IV) in a 59-year-old woman. (a) Axial postcontrast T1-weighted MR image demonstrates a heterogeneously.
Images from the case of an 8-year-old female patient with complex I mitochondrial disease, which was diagnosed when the patient was older than 3 years.
In vivo brain spectra acquired on a healthy volunteer by using a CT-PRESS sequence at 7T. In vivo brain spectra acquired on a healthy volunteer by using.
MRI Atlas of IDH-Wildtype Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes A 3D atlas of glioblastoma location was.
Presentation transcript:

Spectroscopy Voxel-wise IDH-1 Mutation and Non-Enhancing Component of Glioblastoma Daniel M Fountain1, Timothy J Larkin1,2, Natalie R Boonzaier1,2, Jiun-Lin Yan1, and Stephen J Price1,2 1 The Brain Tumour Imaging Laboratory, Division of Neurosurgery and 2 Wolfson Brain Imaging Centre, University of Cambridge, United Kingdom Introduction Isocitrate dehydrogenase 1 gene (IDH-1) mutations have been shown to be present in over 80% of secondary glioblastoma (GBM), but only in 5-12% of primary GBM.1 IDH-1 mutated tumors show increased survival benefit compared to wild-type tumors following further resection of non-enhancing disease.2 We investigated the non-enhancing lesion to identify intrinsic differences between IDH-1 mutated and wild-type tumors using multimodality imaging data. Hypothesis – Non-enhancing components of IDH-1 mutated and wild-type GBM differed significantly. Methods 54 patients were imaged on a Siemens 3T Magnetom Trio with conventional anatomical, diffusion tensor (DTI), dynamic susceptibility contrast perfusion (DSC) and 1H chemical shift imaging (CSI) performed. Of the 54 patients, 8 were diagnosed with IDH-1 mutated GBM. All images were coregistered to the T2-weighted image using the FLIRT toolbox in FSL. The fluid attenuated inversion recovery (FLAIR) region of interest (ROI) was determined excluding the contrast-enhancing tumor and necrosis, thus forming the non-enhancing component for analysis (Figure 1). Analysis was performed at three levels of data (Figure 2): The first and second levels applied a mixed model design to DTI voxelwise and spectroscopy voxelwise data (Figure 2a and 2b respectively). The third level of analysis approached the FLAIR VOI as a whole by averaging all variables across the total volume and modelling using a generalised linear model (Figure 2c). Significance was assessed at the 95% level with Bonferroni correction for multiple testing. Area under the receiver operator characteristics curve (AUC) was computed following multiple logistic regression. All statistical analysis was performed in 64-bit R version 3.0.2.  Figure 1 – Multi-modality data for Patient 1 (IDH-1 wild-type). Data available across all axial slices are shown for each variable of interest. FLAIR ROI – Fluid attenuated inversion recovery peritumoral region of interest, p – isotropic component, q – anisotropic component, rCBV – relative cerebral blood volume, Cho – choline, NAA – N-acetyl-aspartate, mI – myo-inositol, Cr – creatine, Glu – glutamate and glutamine, GSH – glutathione. Figure 2 – Three levels of resolution of imaging data for statistical analysis. A) Voxel-wise DTI data with 2 × 2 × 5mm voxels. B) Voxel-wise spectroscopy data with 10 × 10 × 15-20mm. C) Imaging data averaged over the whole region of interest to provide a single value per variable per patient for statistical analysis. Variable DTI Voxel-wise Spectroscopy Voxel-wise FLAIR ROI Estimate SE t p rCBV 0.096 0.364 0.265 0.775 -0.285 0.348 -0.818 0.384 0.153 0.347 0.440 0.662 0.093 0.103 0.908 0.328 -0.007 0.122 -0.056 0.960 0.101 0.110 0.920 0.363 q -0.087 0.070 -1.248 0.182 -0.148 0.091 -1.637 0.081 -0.105 0.060 -1.747 0.088 Cho:NAA 0.557 0.241 2.311 0.016* 0.801 0.317 2.524 0.008** 0.510 0.236 2.157 0.037* mI:Cr 0.112 0.279 0.400 0.665 0.193 0.277 0.698 0.442 0.179 0.268 0.668 0.508 Cho:Cr 0.190 0.068 2.781 0.004** 0.205 2.525 0.197 2.909 0.006** NAA:Cr 0.003 0.126 0.027 0.977 -0.064 0.131 -0.490 0.571 -0.034 0.127 -0.270 0.789 Glu:Cr -0.603 0.255 -2.359 0.014** -0.878 0.343 -2.557 0.007** 0.211 0.115 1.838 0.073 GSH:Cr -0.293 0.177 -1.656 0.078 -0.369 0.185 -1.992 0.029* -0.195 -1.544 0.130 Results Across all patients, a total of 1,300,632 DTI voxels with data for individual p, q, and rCBV were included with 520 spectroscopy voxels. All statistical results are shown in Table 1. No significant difference in rCBV between IDH-1 wild-type and mutated patients (Estimate -0.285 – 0.153, p = 0.384 – 0.775), or Isotropic (p) and Anisotropic (q) Components (p estimate -0.007 – 0.101, p = 0.328 – 0.960 and q estimate -0.087 – -0.148 p = 0.081 – 0.182) Non-enhancing component showed significant increases in choline relative to creatine in IDH-mutated tumors (Estimate 0.190 – 0.205, p = 0.004-0.008), and associated choline relative to N-acetyl-aspartate (Estimate 0.510–0.801, p = 0.008–0.037) Significantly lower levels of glutamate and glutamine were observed relative to creatine in patients with an IDH-1 mutation (Estimate -0.603 – -0.878, p = 0.007–0.014) Combining these findings with age provided an area under the curve (AUROC) of 0.943. Table 1 – Results of Voxel-wise and ROI multivariable statistical analysis of R132H mutation status. Discussion We propose two hypotheses to explain these findings and the improved survival in patients with IDH-1 mutated tumors: Invasive margins of IDH-mutated tumors are more sensitive to treatment. This correlates with in vitro findings,3 and in vivo IDH-1 mutated tumours with a higher Cho/NAA in the peritumoral margin may be more sensitive to cytotoxic therapies.4 Reduced concentration of glutamate and glutamine identified in IDH-1 mutated tumors is neuroprotective. Glutamate is known to be released in excitotoxic concentrations in glioma cells and in GBM, and is involved in the mechanism of glioma invasion.5 1 Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360:765–773. 2 Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncol. 2014;16:81–91 3 Mohrenz IV, Antonietti P, Pusch S, et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis Int J Program Cell Death.2013;18(11):1416-1425 4 Price SJ, Young AHM, Scotton WJ, et al. Metabolic activity of the invasive microenvironment of glioblastomas determines time to progression: a multimodal MR study. Proc Intl Soc Mag Reson Med. 2015;23:2252 5 Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem. 2008;105(2):287-295